SHERP

High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study

Cited 0 time in webofscience Cited 0 time in scopus
Authors
Kwak, Cheol; Lee, Jeong Ki; Ku, Ja Hyeon
Issue Date
2007-12-27
Publisher
Yonsei University
Citation
Yonsei Med J. 2007 Dec 31;48(6):994-1000.
Keywords
Adrenergic alpha-Antagonists/adverse effects/therapeutic useAgedAsian Continental Ancestry GroupBlood Pressure/drug effectsHumansHypertension/complications/*drug therapy/physiopathologyKoreaMaleMiddle AgedPrazosin/adverse effects/*analogs & derivatives/therapeutic useProspective StudiesProstate/drug effects/pathologyTreatment OutcomeUrodynamics/drug effectsUrologic Diseases/complications/*drug therapy/ethnology
Abstract
PURPOSE: We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS: From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and International Prostate Symptom Score (I-PSS) were assessed. For analysis purposes, patients were stratified according to concomitant hypertension. Of the 200 patients, 173 completed the scheduled eight-week treatment period. RESULTS: At baseline, no differences were evident in the two groups in terms of I-PSS, Qmax, PVR and BP. After eight weeks of treatment-although I-PSS and uroflowmetry parameters were not significantly different in the two groups-systolic and diastolic BP in the non-hypertensive control group were higher than in the hypertensive group (p= 0.001 and p=0.0100, respectively). Changes in I-PSS, uroflowmetry parameters, and BPs measured at week eight post- treatment commencement did not significantly differ between the two groups. Moreover, the addition of 5mg of terazosin to antihypertensives did not cause a significant reduction in either systolic or diastolic BP in either group. CONCLUSION: Adding terazosin to existing antihypertensive regimens did not seem to increase the incidence of adverse events. Our findings suggest that 5mg terazosin is effective and that it has an acceptable safety profile as an add-on therapy for patients with LUTS and concomitant hypertension.
ISSN
0513-5796 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18159592

http://hdl.handle.net/10371/16155
DOI
https://doi.org/10.3349/ymj.2007.48.6.994
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse